

## **Scheme Meeting to sell ADBRI Limited**

| Company/ASX Code  | ADBRI Limited/ABC  |  |
|-------------------|--|--|
| AGM time and date | 10:30am Adelaide time, 12 June 2024  |  |
| Location          | Hindmarsh Ballroom Level 15 Pullman Adelaide, Hindmarsh Square   |  |
| Registry          | Computershare  |  |
| Type of meeting   | EGM: scheme meeting  |  |
| Monitor           | Bob Ritchie assisted by Malcolm Keynes   |  |
| Pre-EGM Meeting   | With Deputy Chair and lead independent director, Samantha Hogg and independent non-executive director, Dean Jenkins. |  |

Monitor Shareholding: an individual (or their associates) involved in the preparation of this voting intention has a shareholding in this company.

## 1. How we intend to vote

| No. | Resolution description |     |
|-----|------------------------|-----|
| 1   | To approve the scheme  | For |

## 2. Summary of Issues and Voting Intentions for EGM

The purpose of the meeting is for independent shareholders to decide on a proposal that CHR (bidder, to form a joint venture with Barro Group) acquires all independently held ADBRI shares at a price of \$3.20. Shareholders who are not independent are CHR and Barro Group, which collectively hold almost 50% of the company. These shareholders are not entitled to vote.

A decision on whether the independent shareholders have voted in favour of the scheme has to pass both of two tests: a 50% majority of the number of shareholders voting and a 75% majority of the number of shares voted.

Because the Australian Shareholders' Association (ASA) does not give financial advice, shareholders who donate their proxy to ASA are encouraged to donate a directed proxy. Any open proxies donated to ASA will be voted in favour of the scheme.

## **ASA Disclaimer**

This document has been prepared by the Australian Shareholders Associa6on Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not cons6tute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommenda6ons of a par6cular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- makes any representa6ons, warran6es or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or informa6on contained in this document; or
- shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any
  statements or informa6on contained in, or omissions from this document; nor for any person's acts or omissions undertaken
  or made in reliance of any such statements, informa6on or omissions.

This document may contain forward-looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cau6oned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obliga6on to disseminate any updates or revisions to any such statements to reflect changed expecta6ons or circumstances.